Cargando…

Individualized recombinant human thrombomodulin (ART-123) administration in sepsis patients based on predicted phenotypes

Detalles Bibliográficos
Autores principales:	Hasegawa, Daisuke, Nishida, Osamu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591969/ https://www.ncbi.nlm.nih.gov/pubmed/31234901 http://dx.doi.org/10.1186/s13054-019-2521-7

Ejemplares similares

Recombinant human thrombomodulin inhibits neutrophil extracellular trap formation in vitro
por: Shimomura, Yasuyo, et al.
Publicado: (2016)

Adequate application of recombinant thrombomodulin for sepsis-associated disseminated intravascular coagulation
por: Iba, Toshiaki
Publicado: (2015)

Coagulation phenotypes in sepsis and effects of recombinant human thrombomodulin: an analysis of three multicentre observational studies
por: Kudo, Daisuke, et al.
Publicado: (2021)

Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis
por: Yamakawa, Kazuma, et al.
Publicado: (2019)

Age-related differences in the survival benefit of the administration of antithrombin, recombinant human thrombomodulin, or their combination in sepsis
por: Wada, Takeshi, et al.
Publicado: (2022)

Web-based application for predicting the potential target phenotype for recombinant human thrombomodulin therapy in patients with sepsis: analysis of three multicentre registries
por: Goto, Tadahiro, et al.
Publicado: (2022)

Efficacy and safety of human soluble thrombomodulin (ART-123) for treatment of patients in France with sepsis-associated coagulopathy: post hoc analysis of SCARLET
por: François, Bruno, et al.
Publicado: (2021)

Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study
por: Kato, Takahiro, et al.
Publicado: (2013)

Recombinant human thrombomodulin attenuated sepsis severity in a non-surgical preterm mouse model
por: Ashina, Mariko, et al.
Publicado: (2020)

Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced DIC
por: Yamakawa, K, et al.
Publicado: (2014)

A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy
por: Kotaka, Masahito, et al.
Publicado: (2020)

Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study
por: Yamakawa, Kazuma, et al.
Publicado: (2011)

Concomitant Versus Individual Administration of Antithrombin and Thrombomodulin for Sepsis-Induced Disseminated Intravascular Coagulation: A Nationwide Japanese Registry Study
por: Umemura, Yutaka, et al.
Publicado: (2018)

Effects of recombinant human soluble thrombomodulin on neutrophil extracellular traps in the kidney of a mouse model of endotoxin shock
por: Harada, Tatsuhiko, et al.
Publicado: (2023)

Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model
por: Iba, Toshiaki, et al.
Publicado: (2009)

Protective Role of Recombinant Human Thrombomodulin in Diabetes Mellitus
por: Okano, Yuko, et al.
Publicado: (2021)

Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes
por: Mori, Shusuke, et al.
Publicado: (2019)

Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
por: Yamakawa, Kazuma, et al.
Publicado: (2013)

Use of Recombinant Human Soluble Thrombomodulin in Patients with Sepsis-Induced Disseminated Intravascular Coagulation after Intestinal Perforation
por: Tagami, Takashi, et al.
Publicado: (2015)

Recombinant human soluble thrombomodulin improves mortality in patients with sepsis especially for severe coagulopathy: a retrospective study
por: Kato, Takahiro, et al.
Publicado: (2018)

Recombinant human soluble thrombomodulin is associated with attenuation of sepsis-induced renal impairment by inhibition of extracellular histone release
por: Akatsuka, Masayuki, et al.
Publicado: (2020)

Efficacy of recombinant human soluble thrombomodulin in disseminated intravascular coagulation
por: Yasuda, T, et al.
Publicado: (2010)

Nanostructured Lipid Carrier Gel Formulation of Recombinant Human Thrombomodulin Improve Diabetic Wound Healing by Topical Administration
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2021)

Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura
por: Nakamura, Kensuke, et al.
Publicado: (2016)

Recombinant Human Thrombomodulin Reduces Mortality and Acute Lung Injury Caused by Septic Peritonitis in Rats
por: Kono, Hiroshi, et al.
Publicado: (2023)

Thrombomodulin: A Bifunctional Modulator of Inflammation and Coagulation in Sepsis
por: Okamoto, Takayuki, et al.
Publicado: (2012)

Factors influencing the effectiveness of recombinant human soluble thrombomodulin on disseminated intravascular coagulation: a retrospective study
por: Asai, Yuki, et al.
Publicado: (2020)

Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
por: Yoshimura, Jumpei, et al.
Publicado: (2015)

Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy
por: Levi, Marcel, et al.
Publicado: (2020)

β1-blocker in sepsis
por: Hasegawa, Daisuke, et al.
Publicado: (2021)

Effects of Thrombomodulin in Reducing Lethality and Suppressing Neutrophil Extracellular Trap Formation in the Lungs and Liver in a Lipopolysaccharide-Induced Murine Septic Shock Model
por: Kato, Yu, et al.
Publicado: (2021)

Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients
por: Miyoshi, Seigo, et al.
Publicado: (2014)

Comparative Analysis of Three Machine-Learning Techniques and Conventional Techniques for Predicting Sepsis-Induced Coagulopathy Progression
por: Hasegawa, Daisuke, et al.
Publicado: (2020)

Effect of Recombinant Human Soluble Thrombomodulin on Coagulation-Related Variables in Patients With Sepsis-Induced Disseminated Intravascular Coagulation: A Retrospective Observational Study
por: Mitaka, Chieko, et al.
Publicado: (2021)

Clinical efficacy of recombinant human soluble thrombomodulin in patients with septic disseminated intravascular coagulation
por: Suzuki, Y, et al.
Publicado: (2013)

Therapeutic Role of Recombinant Human Soluble Thrombomodulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Isshiki, Takuma, et al.
Publicado: (2019)

Protective Effects of Recombinant Human Soluble Thrombomodulin on Lipopolysaccharide-Induced Acute Kidney Injury
por: Nozaki, Yuji, et al.
Publicado: (2020)

Enhanced effect of recombinant human soluble thrombomodulin by ultrasound irradiation in acute liver failure
por: Hoshino, Kota, et al.
Publicado: (2020)

Markers of acute kidney injury in patients with sepsis: the role of soluble thrombomodulin
por: Katayama, Shinshu, et al.
Publicado: (2017)

Recombinant Thrombomodulin Used to Successfully Treat Cronkhite-Canada Syndrome with Disseminated Intravascular Coagulation due to Sepsis in a Compromised Patient
por: Morino, Kahori, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e6o3ku8eljuo81n591mvsh6thj